---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111310"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:12:45.014002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026

## Summary
- Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.
- Phase 2 REVERT Liver Cancer (TTI-101) topline data expected H1 2026; interim showed activity.
- TTI-109 healthy volunteer study started; results also H1 2026.
- REVERT IPF trial preliminary data in October did not meet goals; further analysis underway.
- R&D expenses $3.6M, down from $4.8M; G&A $2.3M, up from $0.9M.

## SEC filing metadata
- accession: 0001104659-25-111310
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/0001104659-25-111310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111310
- JSON: https://secwatch.observer/filing/0001104659-25-111310.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.